Read + Share

Amedeo Smart

Independent Medical Education


Read + Share

Jorgensen KK, Olsen IC, Goll GL, Lorentzen M, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017 May 11. pii: S0140-6736(17)30068.
PMID: 28502609


Free Medical Abstracts
Privacy Policy
Sponsors
Share
About

© Amedeo 1997-2016